Insights
Insights From Our Experts
Articles
Repairing the Patient Journey: How Pharma Can Fix the Obvious – and Not So Obvious – Breaking Points of Nonadherence
When nearly half of all treatment failures stem from nonadherence, the stakes for patients, and for pharma, could not be higher. One of the most persistent barriers in healthcare, leading to preventable hospitalizations, lost lives and…
Treatment Effect Modifiers and Prognostic Factors in Multiple Myeloma: Enabling Smarter Trials and Comparative Research
Multiple myeloma (MM) remains a complex and incurable hematologic malignancy, despite the rapid evolution of therapeutic options over the past decade. With the emergence of novel drug classes—ranging from monoclonal antibody-drug conjugates to CAR-T cell therapies—the…
Expanding the Evidence: Real-World Insights into CDK4/6i Use in Elderly and BIPOC Patients with Metastatic Breast Cancer
Randomized controlled trials have long served as the foundation for establishing treatment efficacy, but they often fall short in representing the full diversity of patients seen in clinical practice. This is especially true in hormone receptor-positive/human…
From Challenges to Solutions: Breaking Barriers to Revolutionize Patient Services
Patients today too often find themselves navigating a myriad of challenges that can make accessing quality healthcare a daunting task. Common obstacles range from financial barriers to long wait times to geographical and technological limitations and…
AI + RWE: Powering Smarter Patient Solutions
Artificial intelligence is transforming how we use real-world evidence (RWE) to improve patient care. As highlighted in Med Ad News’s online edition, pharmalive.com in the article, “AI backs up RWE”, machine learning is helping uncover patterns…
Reimagining Drug Safety: A New Era of Innovation
In a rapidly evolving healthcare landscape, the need for smarter, faster, and more scalable pharmacovigilance (PV) solutions has never been greater. In a recent interview with Pharmaceutical Executive, Vikram Anand shares how EVERSANA is meeting this challenge…
Unlocking the Future of Medical Information Analytics: A Q&A with Michael DeLuca of EVERSANA
EVERSANA’s recent collaboration with 3VUE is reshaping how medical information interactions and metrics are analyzed and visualized to demonstrate value and impact. We sat down with Michael DeLuca, Executive Vice President of Global Medical Affairs &…
Staying Ahead of the Curve in Pharmacovigilance: Mid-Year Pharmacovigilance Inspection Report 2025: Saudi Food & Drug Authority (SFDA)
In an era where patient safety and regulatory compliance are more critical than ever, staying informed about global pharmacovigilance trends is essential. The Saudi Arabia Drug Authority (SFDA) recently released its 2025 Mid-Year Pharmacovigilance Inspection Report,…
Staying Ahead of the Curve in Pharmacovigilance: Module VI Addendum II – Masking of Personal Data in Individual Case Safety (GVP)
In an era where patient safety and regulatory compliance are more critical than ever, staying informed about global pharmacovigilance trends is essential. The EMA and PRAC recently released the “Module VI Addendum II – Masking of…
Insights from BIO with OS Therapies
At this year’s BIO International Convention 2025, pharmaphorum’s Jonah Comstock sat down with Paul Romness, CEO of OS Therapies, and Farah Ahmad, VP of Business Development at EVERSANA, to explore how emerging biotech companies are navigating…